CTLA4 and melanoma: This phenomenon has been observed in NSCLC patients treated with pembrolizumab (an anti-PD-1 antibody), as well as in melanoma patients who showed favorable clinical responses to ipilimumab (an anti-CTLA-4 antibody) (219–221).